Healthcare Providers and Services
Company Overview of N-of-One Therapeutics, Inc.
N-of-One Therapeutics, Inc. provides clinical analysis, curation, and interpretation of a tumor's molecular profile to providers, diagnostic companies, individual physicians, and cancer patients. The company’s solutions include treatment strategy roadmaps, clinical trial matching, and diagnostic strategy roadmaps. Its solutions and services pivot on matching patient-specific tumor molecular profiling data with knowledge on diagnostic technologies and therapeutic options to identify relevant clinical strategies for each patient's unique cancer. The company supports oncologists by delivering content and clinical insights for cancer treatment decisions and diagnostic approaches. N-of-One Therap...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One Therapeutics, Inc.
Chairman and Chief Executive Officer
Compensation as of Fiscal Year 2014.
N-of-One Therapeutics, Inc. Key Developments
CeGaT Selects N-of-One to Provide Clinical Interpretation for Next-Generation Sequencing Tests
Jul 1 14
CeGaT has announced an agreement with N-of-One, Inc. Under this agreement, N-of-One will provide clinical interpretation for CeGaT's next-generation sequencing (NGS) tests done for cancer patients. Financial terms of the agreement are not disclosed. CeGaT has developed a next-generation sequencing panel to analyze more than 550 cancer-relevant genes in a tumor sample simultaneously. Knowledge about the relevant mutations in a tumor helps clinicians select the most effective therapeutic strategies. CeGaT is partnering with N-of-One to provide high quality, up-to-date interpretation of mutations with very rapid turnaround times.
N-of-One Announces Agreement with Mayo Clinic to Provide Clinical Interpretation Support for Molecular Diagnostics Program
May 21 14
N-of-One announced an agreement with Mayo Clinic to provide access to clinical interpretation information to aid in highly complex molecular diagnostics. Under the terms of the agreement, in select cases, N-of-One solutions will assist in the identification of biological and clinical knowledge, therapeutic options, and potential clinical trials for patients who undergo next generation cancer sequencing. This will help to translate knowledge specifically related to individual patients' tumors into molecularly informed, personalized treatment decisions. Mayo Clinic will use the clinical interpretation services for Mayo Medical Laboratories, a global reference laboratory operating within Mayo Clinic's Department of Laboratory Medicine and Pathology, as well as in its Center for Individualized Medicine, which discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.
N-of-One Announces Agreement with Guardant Health to Provide Clinical Decision Support for Guardant360
May 19 14
N-of-One announced an agreement with Guardant Health to provide clinical decision support for Guardant360, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. N-of-One's clinical interpretation provides relevant biological and clinical knowledge related to the mutation profile of the identified tumor DNA, and links this knowledge to relevant therapeutic strategies, including clinical trials, to support oncologists in making molecularly-informed, personalized treatment decisions.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 16, 2013